Zymeworks Inc. — Investor Relations & Filings

Zymeworks Inc. is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company focuses on creating transformational therapies for patients with difficult-to-treat cancers and other serious diseases. Its product pipeline is driven by proprietary and clinically validated technology platforms for engineering next-generation antibody-drug conjugates (ADCs) and multispecific antibody therapeutics. Zymeworks operates as a royalty-driven organization with integrated in-house research and development capabilities, managing a portfolio of licensed healthcare assets while advancing its own novel therapeutic candidates.